Save the dateLab Data Summit 2027April 8 · PhiladelphiaRequest your invitation

Resources / Case study / Hematology & oncology

Case study · Acute lymphoblastic leukemia

A precise ALL signal.
A repeatable path
to HCP engagement.

How a leading biopharmaceutical company used biomarker-specific lab findings, patient segmentation, and weekly alerts to focus engagement with hematologists and oncologists.

An illustrative path from a BCR-ABL Minor e1a2 lab signal to patient segmentation and weekly HCP alertsPROGRAM BIOMARKER CRITERIONBCR-ABL Minor (e1a2)Patient segmentationProgram-defined cohortsWeekly HCP alertsHematology & oncology
How lab findings supported patient segmentation and weekly HCP alerts.
ClientA leading biopharmaceutical company
Therapeutic areaHematology / Oncology · Acute lymphoblastic leukemia (ALL)
Prognos serviceLab-based HCP alerts
39Average newly diagnosed patients
identified per week
5Average relapsed patients
identified per week
WednesdayScheduled delivery of weekly
HCP alerts

Weekly patient averages reflect January–August 2024 and the patient-segmentation criteria used in this program.

2018 → 2025Program start · Renewed for 2025

A partnership built around recurring value.

Launched in February 2018 and renewed for 2025, the program reflects a sustained commitment to lab-based patient finding and HCP engagement.

The challenge

A specific biomarker.
A focused patient population.
A need for actionable context.

The client’s commercial team needed to identify patients with specific ALL-related lab findings, distinguish newly diagnosed and relapsed patient groups, and connect those findings to the hematologists and oncologists involved in care.

Find the clinical detail.

The team needed visibility into BCR-ABL Minor (e1a2) results to identify findings that met the program’s biomarker criteria.

Distinguish patient groups.

Distinguishing newly diagnosed and relapsed patient groups would help the team tailor HCP engagement to different clinical contexts.

Support field-team planning.

Field teams needed relevant lab findings linked to HCPs and delivered on a consistent schedule to support engagement planning.

How Prognos helped

Connect lab findings
to relevant HCPs.

Prognos implemented a lab-based alert program using harmonized lab data, biomarker-specific selection, patient segmentation, and HCP mapping.

Identify the signal.

Prognos identified positive BCR-ABL Minor (e1a2) findings that met the program’s clinical criteria.

Segment patients.

Patients were organized into newly diagnosed and relapsed groups using the program’s segmentation criteria.

Connect to HCPs.

De-identified patient results were mapped to treating hematologists and oncologists to support commercial follow-up.

Deliver weekly.

HCP alerts were delivered each Wednesday, covering lab activity from the previous Saturday through Friday.

A consistent delivery schedule

Weekly lab insights.
A reliable input for field teams.

Each Wednesday, field teams received alerts based on the previous Saturday–Friday lab activity, creating a consistent schedule for reviewing findings and planning HCP engagement.

Each delivery connected relevant lab findings with patient segments and HCP context, helping teams incorporate those insights into their existing workflows.

Program results

Identify patients.
Understand their clinical context.

From January through August 2024, the program identified an average of 39 newly diagnosed and 5 relapsed patients per week.

Biomarker-specific patient finding.

Biomarker-specific criteria helped the team identify patients relevant to the program’s commercial objectives.

More context for HCP engagement.

Distinguishing newly diagnosed and relapsed patient groups gave the team additional context for HCP education and follow-up.

Patient identification across multiple states.

California, Florida, Texas, New Jersey, and North Carolina were among the states with the highest program volumes.

Results reflect this program during January–August 2024. Newly diagnosed and relapsed groups were defined using the program’s segmentation criteria. A biomarker result alone does not establish diagnosis, relapse, or treatment eligibility.

Why the lab detail matters

Bring clinical detail
into commercial planning.

Diagnostic findings, disease subtypes, and longitudinal testing add clinical detail to the patient journey. Bringing that detail into an HCP alert program helps commercial teams focus on the patient populations and providers relevant to their goals.

Define the population with more precision.

Biomarker findings and longitudinal lab results help teams define relevant patient populations with greater clinical detail.

Read the ALL perspective →

Make insights part of the workflow.

Connecting clinical criteria, patient segments, and relevant HCPs in a recurring alert program helps teams apply lab insights to engagement planning.

Explore Prognos Oncology →

A closer look

About the program.

How did Prognos identify relevant patients?

Prognos identified BCR-ABL Minor (e1a2) findings, applied the program’s patient-segmentation criteria, and mapped results to treating hematologists and oncologists. The program focused on a specific biomarker-defined population within ALL.

How frequently were the alerts delivered?

Alerts were delivered weekly on Wednesday, covering the previous Saturday–Friday lab activity.

When were these results measured?

The program averaged 39 newly diagnosed and 5 relapsed patients identified per week during January–August 2024.

Build a more focused
HCP engagement program.

Tell us which biomarkers and patient populations matter to your team. We’ll help define a lab-based approach that supports your HCP engagement goals.

Unlocking the Power of Data to Improve Health.
Explore a similar program →
Cookie Preferences